NCT01822691View on ClinicalTrials.gov

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

INCB024360

INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01822691 - Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter